GlassScriptPhysician profile
Julie Spivack
NPI 1316939226
$11,675.40
in general payments reported to CMS, 2019-2025
38 companies · $2,714 in 2025
The $2,714 reported for 2025 was more than what 96% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,749 · 2020: $342 · 2021: $852 · 2022: $1,765 · 2023: $1,965 · 2024: $2,289 · 2025: $2,714.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,949 · Education: $18.57.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,949.39 |
| Education | $18.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,504.96 | 2019-2025 | Rinvoq, Skyrizi, Linzess |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,398.21 | 2019-2025 | Xifaxan, Plenvu, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $1,109.97 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Janssen Biotech, INC. | $796.76 | 2019-2025 | Stelara, Tremfya, Simponi |
| Celgene Corporation | $700.20 | 2021-2024 | Zeposia |
| Pfizer INC. | $633.19 | 2019-2025 | |
| Qol Medical, LLC | $603.98 | 2022-2025 | Sucraid, Sucraid |
| Gilead Sciences, INC. | $492.44 | 2019-2025 | |
| Ipsen Biopharmaceuticals, INC | $453.32 | 2024-2025 | Iqirvo |
| Ardelyx, INC. | $406.06 | 2022-2025 | Ibsrela |
| Foundation Medicine, INC. | $350.43 | 2019 | |
| Madrigal Pharmaceuticals | $344.76 | 2024-2025 | Rezdiffra |
| Intercept Pharmaceuticals, INC. | $327.37 | 2019-2025 | Ocaliva |
| Genzyme Corporation | $171.56 | 2022-2025 | |
| Janssen Scientific Affairs, LLC | $125.00 | 2019 |
Show all 37 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$77,759.52 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julie Spivack listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.